Formulation: A solid
Formal Name: 17α-hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile-2,2,4,8,11,11,20,20-d8
Purity: ≥99% deuterated forms (d1-d8)
Formula Markup: C20H17D8NO2
Formula Weight: 319,5
Shelf life (days): 1460
CAS Number: 2376035-92-4
Notes: Dienogest-d8 is intended for use as an internal standard for the quantification of dienogest (Item No. 21257) by GC- or LC-MS. Dienogest is a synthetic progestin and progesterone receptor (PR) agonist (EC50s = 3.4-10.5 nM in transactivation assays).{46786} It is selective for PR over estrogen receptor α (ERα) and ERβ, as well as glucocorticoid and mineralocorticoid receptors (EC50s = >3,000 nM for all), as well as sex hormone-binding globulin (SHBG) and cortisol-binding globulin (CBG; IC50s = 900-950 and 7,970 nM, respectively, in radioligand binding assays). It also inhibits dihydrotestosterone-induced transactivation of the androgen receptor (EC50s = 420.6-775 nM). Dienogest (0.1, 0.3, and 1 mg/kg per day for 21 days, p.o.) reduces lesion formation in a rat model of endometriosis.{46787} It reduces 17β-estradiol benzoate-dependent tumor growth in an MCF-7 ovariectomized mouse xenograft model when administered at doses of 0.1 and 1 mg/kg per day for 28 days.{46788} Formulations containing dienogest in combination with estradiol valerate have been used as contraceptives.